T-Cell Modulatory Multimeric Polypeptides and Methods of Use Thereof
The present disclosure provides variant immunomodulatory polypeptides, and fusion polypeptides comprising the variant immunomodulatory peptides. The present disclosure provides T-cell modulatory multimeric polypeptides, and compositions comprising same, where the T-cell modulatory multimeric polypeptides comprise a variant immunomodulatory polypeptide of the present disclosure. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the T-cell modulatory multimeric polypeptides, and host cells comprising the nucleic acids. The present disclosure provides methods of modulating the activity of a T cell; the methods comprise contacting the T cell with a T-cell modulatory multimeric polypeptide of the present disclosure.
1 .- 132 . (canceled)
133 . A heterodimer comprising
a) a first polypeptide comprising:
i) a virus-associated peptide other than a human papillomavirus peptide; and
ii) a β2-microglobulin (β2M) polypeptide; and
b) a second polypeptide comprising:
i) two copies of a variant IL-2 polypeptide, each copy comprising an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:44, wherein amino acid 16 is other than a His and amino acid 42 is other than a Phe, wherein the two variant IL-2 polypeptides are linked by a peptide linker;
ii) a major histocompatibility complex (MHC) Class I heavy chain polypeptide; and
iii) an immunoglobulin (Ig) Fc polypeptide, and
wherein the heterodimer comprises a disulfide bond that covalently links a Cys residue in the β2M polypeptide to a Cys residue in the MHC class I heavy chain polypeptide,
wherein the heterodimer presents a viral epitope to a T cell receptor,
wherein the heterodimer comprises one or more independently selected peptide linkers interposed between one or more of the components of the first and second polypeptides, and
wherein the percent sequence identity is determinable by a sequence alignment performed using BLAST.
134 . A nucleic acid comprising
a) a first nucleotide sequence encoding a first polypeptide comprising:
i) a virus-associated peptide other than a human papillomavirus peptide; and
ii) a β2-microglobulin (β2M) polypeptide;
b) a second nucleotide sequence encoding a second polypeptide comprising:
i) a major histocompatibility complex (MHC) class I HLA-A heavy chain polypeptide;
ii) two copies of a variant IL-2 polypeptide, each copy comprising an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:44, wherein amino acid 16 is other than a His and amino acid 42 is other than a Phe, and wherein the percent sequence identity is determinable by a sequence alignment performed using BLAST; and
iii) an immunoglobulin (Ig) Fc polypeptide,
wherein the percent sequence identity is determinable by a sequence alignment performed using BLAST.
135 . A plurality of cells genetically modified with the nucleic acid of claim 134 .
136 . A method comprising culturing a plurality of genetically modified cells according to claim 135 in a culture medium under conditions such that the cell synthesizes the first and second polypeptides.
137 . First and second nucleic acids, wherein
a) the first nucleic acid comprises a nucleotide sequence encoding a first polypeptide comprising:
i) a virus-associated peptide other than a human papillomavirus peptide; and
ii) a β2-microglobulin (β2M) polypeptide;
b) the second nucleic acid comprises a nucleotide sequence encoding a second polypeptide comprising:
i) a major histocompatibility complex (MHC) class I HLA-A heavy chain polypeptide;
ii) two copies of a variant IL-2 polypeptide, each copy comprising an amino acid sequence having at least 95% amino acid sequence identity to the amino acid sequence set forth in SEQ ID NO:44,
wherein amino acid 16 is other than a His and amino acid 42 is other than a Phe, and wherein the percent sequence identity is determinable by a sequence alignment performed using BLAST; and
iv) an immunoglobulin (Ig) Fc polypeptide,
wherein the percent sequence identity is determinable by a sequence alignment performed using BLAST.
138 . A plurality of cells genetically modified with the nucleic acids of claim 137 .
139 . A method comprising culturing a plurality of genetically modified cells according to claim 138 in a culture medium under conditions such that the cell synthesizes the first and second polypeptides.